Press Releases May 27, 2026 07:01 AM

Invivyd to Participate in Upcoming Investor Events

Invivyd announces participation in key June 2026 investor conferences focused on healthcare and infectious diseases.

By Sofia Navarro IVVD

Invivyd, Inc., a U.S.-based biopharmaceutical company specializing in antibody treatments for viral infectious diseases, announced it will participate in several investor events in June 2026, including the Jefferies Global Healthcare Conference, H.C. Wainwright Virtual Fireside Chat, and BTIG Infectious Disease Day. The company highlights its proprietary antibody technology platform and recent FDA emergency use authorization for a monoclonal antibody targeting SARS-CoV-2.

Invivyd to Participate in Upcoming Investor Events
IVVD

Key Points

  • Invivyd to present and engage with investors at multiple healthcare-focused events in June 2026.
  • Company uses a proprietary platform to develop antibody treatments for serious viral infectious diseases, starting with COVID-19.
  • Received FDA emergency use authorization for a monoclonal antibody treatment in March 2024, marking a milestone for its pipeline.

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:

2026 Jefferies Global Healthcare Conference in New York
Fireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ET
Location: New York, NY
Webcast Link

H.C. Wainwright “HCW @ Home” Series
Fireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ET
Location: Virtual
Webcast Link

BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
1x1 Meetings
Location: Virtual

Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived following each event.

The management team will host investor meetings at the Jeffries Conference, following the H.C. Wainwright Virtual Fireside Chat, and as part of the BTIG Infectious Disease Day 2026. Investors participating in these events who are interested in meeting with Invivyd management should contact their Jeffries, H.C. Wainwright, or BTIG representatives.

About Invivyd  
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:
Media Relations
(781) 208-0160
[email protected]

Investor Relations
(781) 208-1747
[email protected]


Risks

  • Uncertainty regarding market uptake and commercial success of the EUA-authorized monoclonal antibody.
  • Dependence on successful R&D and regulatory approvals for pipeline products beyond current EUA antibody.
  • Potential impacts of broader infectious disease market dynamics and competition in the biopharmaceutical sector.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026